#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Henoch-Schonlein purpura nephritis Acute myeloid leukaemia (in remission) Adenocarcinoma gastric Superficial vein thrombosis Keratosis follicular Fibrosarcoma Growth hormone deficiency Retinal dystrophy Endometrial adenocarcinoma Mixed-type liposarcoma Sjogren's syndrome Adrenocortical carcinoma Colorectal adenocarcinoma Richter's syndrome Penile cancer More trials…

    Learn about Rare Diseases

    Chordoma – Diagnostics Pleomorphic leiomyosarcoma – Treatment Primary hyperoxaluria – Trials in Disease Factor VIII deficiency – Life with Disease Systemic mastocytosis – Treatment Retinitis pigmentosa Pleural mesothelioma malignant – Trials in Disease Rhabdomyosarcoma recurrent – Trials in Disease Rett syndrome – Basic Information Acute respiratory distress syndrome – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Aon-D21 Terbinafine Hydrochloride Lenacapavir Sodium Rosuvastatin Buloxibutid Acetylcholine Chloride Nilotinib Pregabalin Ceftriaxone Sodium Pioglitazone Estradiol Hemihydrate Methoxyflurane Glucose, Anhydrous Bms-986442 Mirvetuximab Soravtansine Clemastine Human Plasma Protein Oxazepam Vafidemstat Benzyl Alcohol More therapies…

    Learn about Your Condition

    Thrombocytosis Frontotemporal dementia Strongyloidiasis Heart transplant Impaired gastric emptying Thrombolysis Mitral valve disease Polycythaemia vera Herpes zoster Acute leukaemia Primary hyperaldosteronism Nervous system disorder Mitral valve incompetence Diminished ovarian reserve Tendon rupture More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Centrum Medyczne LukaMed Joanna Łuka

Centrum Medyczne LukaMed Joanna Łuka

Ul. Mickiewicza 39, Chojnice, 89-600, Poland

Want to learn more about this study or check if you can participate? Contact us.

  • Testing SAR442970 compared to placebo in adults with moderate to severe Crohn’s disease

    Recruiting

    2 1
    Investigated Drugs:
    • Sar442970
    Belgium Czechia France Germany Poland Spain

  • Study of maridebart cafraglutide to reduce cardiovascular problems in overweight or obese patients with atherosclerotic cardiovascular disease

    Recruiting

    3 1
    Investigated Diseases:
    • Arteriosclerosis
    Investigated Drugs:
    • Maridebart Cafraglutide
    Austria Belgium Bulgaria Czechia Denmark Finland +12

  • Study of RO7790121 (afimkibart) for Treatment and Long-term Management in Adults with Moderate to Severe Crohn’s Disease

    Recruiting

    3 1
    Investigated Diseases:
    • Crohn’s disease
    Investigated Drugs:
    • Ro7790121
    Austria Belgium Bulgaria Croatia Czechia Denmark +10

  • Study on the Safety and Effectiveness of Lutikizumab and Adalimumab for Adults with Moderate to Severe Ulcerative Colitis

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Colitis ulcerative
    Investigated Drugs:
    • Lutikizumab
    • Adalimumab
    Austria Belgium Bulgaria Croatia Estonia France +12

  • Comparison of Risankizumab and Vedolizumab for Treatment of Moderate to Severe Ulcerative Colitis in Adults Who Have Not Received Targeted Therapies

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Risankizumab
    • Vedolizumab
    Austria Bulgaria Croatia Czechia Estonia Finland +14

  • Study on the Effects of IDP-118 Lotion (Tazarotene and Halobetasol Propionate) for Children with Moderate to Severe Plaque Psoriasis

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • TAZAROTENE
    • HALOBETASOL PROPIONATE
    Poland

  • Study on Guselkumab for Patients with Moderate to Severe Crohn’s Disease

    Not recruiting

    3 1
    Investigated Drugs:
    • Guselkumab
    Croatia Czechia France Germany Hungary Italy +4

  • Study on the Safety and Effectiveness of Naronapride for Adults with Moderate Idiopathic or Diabetic Gastroparesis

    Not recruiting

    2 1
    Investigated Diseases:
    • Diabetic gastroparesis
    • Impaired gastric emptying
    Investigated Drugs:
    • Naronapride Dihydrochloride Trihydrate
    Austria Belgium France Germany Italy Latvia +2

  • Study Comparing AVT16 and Vedolizumab for Adults with Moderate to Severe Ulcerative Colitis

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Acute haemorrhagic ulcerative colitis
    Investigated Drugs:
    • Sodium Chloride
    • Vedolizumab
    Bulgaria Croatia Czechia Greece Hungary Italy +5

  • Study on Rifamycin SV for Patients with Mild to Moderate Left-Sided Ulcerative Colitis

    Not recruiting

    2 1
    Investigated Diseases:
    • Colitis ulcerative
    Investigated Drugs:
    • Rifamycin Sodium
    Bulgaria Estonia Hungary Latvia Lithuania Poland +1
1 2
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!